Edwards Lifesciences is on track to earn an expanded indication for its Sapien 3 transcatheter aortic valve replacement (TAVR) system – possibly earlier than expected – as the Sapien 3 observational study shows that patients deemed to be at intermediate risk for surgical complications may have better one-year outcomes with the TAVR system than surgical valve replacement.
Vinod Thourani of Emory University in Atlanta presented these results of the Sapien 3 observational study April 3 at the...